Evidence map›Paper›PMID 29890854›Full record

ArticleDrug delivery2018

Dipeptide-modified nanoparticles to facilitate oral docetaxel delivery: new insights into PepT1-mediated targeting strategy.

Yuqian Du, Chutong Tian, Menglin Wang, Di Huang, Wei Wei, Yan Liu, Lin Li, Bingjun Sun, Longfa Kou, Qiming Kan and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.5field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Transporter-Mediated Drug Delivery.Molecules (Basel, Switzerland) · 2023
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Yuqian Dua Department of Pharmaceutics, Wuya College of Innovation , Shenyang Pharmaceutical University , Shenyang , P.R. China.
Chutong Tiana Department of Pharmaceutics, Wuya College of Innovation , Shenyang Pharmaceutical University , Shenyang , P.R. China.
Menglin Wanga Department of Pharmaceutics, Wuya College of Innovation , Shenyang Pharmaceutical University , Shenyang , P.R. China.
Di Huangb Department of Clinical Pharmacology, School of Pharmacy , Dalian Medical University , Dalian , P.R. China.
Wei Weia Department of Pharmaceutics, Wuya College of Innovation , Shenyang Pharmaceutical University , Shenyang , P.R. China.
Yan Liua Department of Pharmaceutics, Wuya College of Innovation , Shenyang Pharmaceutical University , Shenyang , P.R. China.
Lin Lia Department of Pharmaceutics, Wuya College of Innovation , Shenyang Pharmaceutical University , Shenyang , P.R. China.
Bingjun Suna Department of Pharmaceutics, Wuya College of Innovation , Shenyang Pharmaceutical University , Shenyang , P.R. China.
Longfa Koua Department of Pharmaceutics, Wuya College of Innovation , Shenyang Pharmaceutical University , Shenyang , P.R. China.
Qiming Kanc School of Life Science and Biopharmaceutics , Shenyang Pharmaceutical University , Shenyang , P.R. China.
Kexin Liub Department of Clinical Pharmacology, School of Pharmacy , Dalian Medical University , Dalian , P.R. China.
Cong Luoa Department of Pharmaceutics, Wuya College of Innovation , Shenyang Pharmaceutical University , Shenyang , P.R. China.
Jin Suna Department of Pharmaceutics, Wuya College of Innovation , Shenyang Pharmaceutical University , Shenyang , P.R. China.
Zhonggui Hea Department of Pharmaceutics, Wuya College of Innovation , Shenyang Pharmaceutical University , Shenyang , P.R. China.
Shenyang Pharmaceutical University · CNDalian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oligopeptide transporter 1 (PepT1) has been a striking prodrug-designing target. However, the underlying mechanism of PepT1 as a target to facilitate the oral absorption of nanoparticles (NPs) remains unclear. Herein, we modify Poly (lactic-co-glycolic acid) (PLGA) NPs with the conjugates of dipeptides (L-valine-valine, L-valine-phenylalanine) and polyoxyethylene (PEG Mw: 1000, 2000) stearate to facilitate oral delivery of docetaxel (DTX) to investigate the oral absorption mechanism and regulatory effects on PepT1 of the dipeptide-modified NPs. The cellular uptake of the dipeptide-modified NPs is more efficient than that of the unmodified NPs in the stably transfected hPepT1- Hela cells and Caco-2 cells, suggesting the involvement of PepT1 in the endocytosis of NPs. The internalization of the dipeptide-modified NPs is proved to be a proton-dependent process. Moreover, the L-valine-valine modified NPs with shorter PEG chain exhibit distinct advantages in terms of intestinal permeability and oral absorption, resulting in significantly improved oral bioavailability of DTX. In summary, PepT1 could serve as a desirable target for oral nanoparticulate drug delivery and the dipeptide-modified NPs represent a promising nanoplatform to facilitate oral delivery of hydrophobic drugs with low bioavailability.

Indexed as

Administration, OralAnimalsBiological AvailabilityCaco-2 CellsDipeptidesDocetaxelDrug CarriersDrug Delivery SystemsEndocytosisHeLa CellsHumansIntestinal AbsorptionIntestinal MucosaLactic AcidMaleNanoparticlesDipeptidesDocetaxelDrug CarriersLactic AcidPeptide Transporter 1Polyethylene GlycolsPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerProdrugsSLC15A1 protein, humanTaxoidsDipeptide-modified nanoparticledocetaxeloral bioavailabilityPepT1-mediated endocytosisregulatory mechanism

Identifiers

PMID29890854
PMCPMC6058494
OpenAlexW2808645248

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.